SG44645A1 - Salts of peptides with carboxy - terminated polyesters - Google Patents

Salts of peptides with carboxy - terminated polyesters

Info

Publication number: SG44645A1
Authority: SG; Singapore
Prior art keywords: carboxy; peptides; salts; terminated polyesters; polyesters
Prior art date: 1992-05-28

Application number

SG1996004921A

Other languages

English (en)

Inventor

Francis Gowland Hutchinson

Original Assignee

Zeneca Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-28

Filing date

1993-05-25

Publication date

1997-12-19

1993-05-25 Application filed by Zeneca Ltd filed Critical Zeneca Ltd

1997-12-19 Publication of SG44645A1 publication Critical patent/SG44645A1/en

Links

125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 title 1
229920000728 polyester Polymers 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Polyesters Or Polycarbonates (AREA)

SG1996004921A 1992-05-28 1993-05-25 Salts of peptides with carboxy - terminated polyesters SG44645A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB@@@@A GB9211268D0 (en)	1992-05-28	1992-05-28	Salts of basic peptides with carboxyterminated polyesters

Publications (1)

Publication Number	Publication Date
SG44645A1 true SG44645A1 (en)	1997-12-19

Family

ID=10716132

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG1996004921A SG44645A1 (en)	1992-05-28	1993-05-25	Salts of peptides with carboxy - terminated polyesters

Country Status (33)

Country	Link
US (3)	US5889110A (cs)
JP (1)	JPH08501064A (cs)
KR (1)	KR100293882B1 (cs)
AT (1)	AT407702B (cs)
AU (1)	AU682310B2 (cs)
BE (1)	BE1006143A3 (cs)
CA (1)	CA2136751C (cs)
CH (2)	CH690491A5 (cs)
CZ (1)	CZ292449B6 (cs)
DE (2)	DE4392401T1 (cs)
DK (1)	DK176134B1 (cs)
ES (1)	ES2107357B1 (cs)
FI (1)	FI112603B (cs)
FR (1)	FR2691631B1 (cs)
GB (3)	GB9211268D0 (cs)
GR (1)	GR1001550B (cs)
HK (1)	HK133097A (cs)
HU (1)	HUT70177A (cs)
IE (1)	IE74715B1 (cs)
IL (1)	IL105710A (cs)
IT (1)	IT1271139B (cs)
LU (1)	LU88559A1 (cs)
MC (1)	MC2330A1 (cs)
NL (1)	NL195056C (cs)
NO (1)	NO311006B1 (cs)
NZ (1)	NZ252268A (cs)
RU (1)	RU2152225C1 (cs)
SE (1)	SE501970C2 (cs)
SG (1)	SG44645A1 (cs)
SK (1)	SK280320B6 (cs)
TW (1)	TW223018B (cs)
WO (1)	WO1993024150A1 (cs)
ZA (1)	ZA933358B (cs)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9211268D0 (en) *	1992-05-28	1992-07-15	Ici Plc	Salts of basic peptides with carboxyterminated polyesters
US6582728B1 (en) *	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
US5665428A (en) *	1995-10-25	1997-09-09	Macromed, Inc.	Preparation of peptide containing biodegradable microspheres by melt process
US5968895A (en) *	1996-12-11	1999-10-19	Praecis Pharmaceuticals, Inc.	Pharmaceutical formulations for sustained drug delivery
JP4642946B2 (ja) *	1996-12-20	2011-03-02	アルザコーポレイション	ゲル組成物および方法
US20020182258A1 (en) *	1997-01-22	2002-12-05	Zycos Inc., A Delaware Corporation	Microparticles for delivery of nucleic acid
US6127341A (en) *	1997-06-20	2000-10-03	Novo Nordisk A/S	Compounds with growth hormone releasing properties
US6117949A (en) *	1998-10-01	2000-09-12	Macromed, Inc.	Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en)	1997-10-03	2001-03-13	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US20030166525A1 (en) *	1998-07-23	2003-09-04	Hoffmann James Arthur	FSH Formulation
EP1240896A3 (en) *	1998-07-23	2003-03-26	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Encapsulation of water soluble peptides
US20070009605A1 (en) *	1998-07-23	2007-01-11	Ignatious Francis X	Encapsulation of water soluble peptides
TW570805B (en) *	1998-09-01	2004-01-11	Hoffmann La Roche	Water-soluble pharmaceutical composition in an ionic complex
US7662409B2 (en)	1998-09-25	2010-02-16	Gel-Del Technologies, Inc.	Protein matrix materials, devices and methods of making and using thereof
CO5160256A1 (es) *	1999-02-08	2002-05-30	Zentaris Ag	Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
US7018645B1 (en)	2000-04-27	2006-03-28	Macromed, Inc.	Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US6495164B1 (en) *	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
AU6815901A (en) *	2000-06-02	2001-12-17	Zycos Inc	Delivery systems for bioactive agents
MXPA03002643A (es) *	2000-09-28	2003-06-19	Chiron Corp	Composiciones de microparticulas y metodos para producirlas.
CN1507357A (zh) *	2000-10-31	2004-06-23	PRҩƷ��޹�˾	提高生物活性分子传递的方法和组合物
WO2003000156A1 (en)	2001-06-22	2003-01-03	Southern Biosystems, Inc.	Zero-order prolonged release coaxial implants
US6873915B2 (en) *	2001-08-24	2005-03-29	Surromed, Inc.	Peak selection in multidimensional data
US20030095928A1 (en) *	2001-09-19	2003-05-22	Elan Pharma International Limited	Nanoparticulate insulin
WO2003034988A2 (en) *	2001-10-19	2003-05-01	Idexx Laboratories, Inc.	Injectable compositions for the controlled delivery of pharmacologically active compound
US20070196415A1 (en) *	2002-11-14	2007-08-23	Guohua Chen	Depot compositions with multiple drug release rate controls and uses thereof
DE60239952D1 (de) *	2001-11-14	2011-06-16	Durect Corp	Injizierbare depotzusammensetzungen und deren verwendung
EP1446101B1 (en) *	2001-11-14	2011-03-23	Durect Corporation	Catheter injectable depot compositions and uses thereof
DE10206517A1 (de) *	2002-02-16	2003-09-04	Stoess & Co Gelatine	Depotarzneimittel, Trägermaterialien für Depotarzneimittel und Verfahren zu deren Herstellung
ES2292655T3 (es) *	2002-03-15	2008-03-16	Alrise Biosystems Gmbh	Microparticulas y procedimiento para su preparacion.
US9101540B2 (en) *	2002-04-12	2015-08-11	Alkermes Pharma Ireland Limited	Nanoparticulate megestrol formulations
US7649023B2 (en)	2002-06-11	2010-01-19	Novartis Ag	Biodegradable block copolymeric compositions for drug delivery
AR039729A1 (es) *	2002-06-25	2005-03-09	Alza Corp	Formulaciones de deposito de corta duracion
KR101041767B1 (ko) *	2002-06-25	2011-06-17	다케다 야쿠힌 고교 가부시키가이샤	서방성 조성물의 제조 방법
US20040001889A1 (en)	2002-06-25	2004-01-01	Guohua Chen	Short duration depot formulations
AU2002359397B2 (en) *	2002-07-31	2009-01-29	Durect Corporation	Injectable depot compositions and uses thereof
CN1684663A (zh) *	2002-07-31	2005-10-19	阿尔萨公司	可注射的多模式聚合物储库组合物以及其用途
ES2377318T3 (es)	2002-09-06	2012-03-26	Cerulean Pharma Inc.	Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
RU2355385C2 (ru)	2002-11-06	2009-05-20	Алза Корпорейшн	Композиции пролонгированного действия с контролируемым высвобождением
US20050048099A1 (en) *	2003-01-09	2005-03-03	Allergan, Inc.	Ocular implant made by a double extrusion process
EP1911763B1 (en)	2003-01-28	2010-08-11	Ironwood Pharmaceuticals, Inc.	Compositions for the treatment of gastrointestinal disorders
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
DK1610822T4 (en) *	2003-04-02	2019-01-14	Ares Trading Sa	Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
US20040224024A1 (en) *	2003-04-23	2004-11-11	Massachusetts Institute Of Technology	Controlled drug release formulations containing polyion complexes
US20050112087A1 (en) *	2003-04-29	2005-05-26	Musso Gary F.	Pharmaceutical formulations for sustained drug delivery
EP1638595B1 (en) *	2003-06-20	2013-03-20	Ares Trading S.A.	Freeze-dried fsh / lh formulations
WO2005034852A2 (en)	2003-08-26	2005-04-21	Gel-Del Technologies, Inc.	Protein biomaterials and biocoacervates and methods of making and using thereof
US20050049210A1 (en) *	2003-08-27	2005-03-03	Idexx Laboratories, Inc.	Methods for the controlled delivery of pharmacologically active compounds
CA2544678C (en)	2003-11-05	2013-12-31	Sunesis Pharmaceuticals, Inc.	Modulators of cellular adhesion
WO2005055945A2 (en)	2003-12-08	2005-06-23	Gel-Del Technologies, Inc.	Mucoadhesive drug delivery devices and methods of making and using thereof
TW200529890A (en) *	2004-02-10	2005-09-16	Takeda Pharmaceutical	Sustained-release preparations
WO2005074968A2 (en) *	2004-02-10	2005-08-18	Universiteit Maastricht	Medical use of basic peptides
US8562505B2 (en) *	2004-02-20	2013-10-22	The Children's Hospital Of Philadelphia	Uniform field magnetization and targeting of therapeutic formulations
US9028829B2 (en) *	2004-02-20	2015-05-12	The Children's Hospital Of Philadelphia	Uniform field magnetization and targeting of therapeutic formulations
US7846201B2 (en) *	2004-02-20	2010-12-07	The Children's Hospital Of Philadelphia	Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
EP1674082A1 (de) *	2004-12-22	2006-06-28	Zentaris GmbH	Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
DK2444079T3 (en)	2005-05-17	2017-01-30	Sarcode Bioscience Inc	Compositions and Methods for the Treatment of Eye Diseases
US20070106271A1 (en) *	2005-11-09	2007-05-10	Searete Llc, A Limited Liability Corporation	Remote control of substance delivery system
US8945598B2 (en) *	2005-12-29	2015-02-03	Cordis Corporation	Low temperature drying methods for forming drug-containing polymeric compositions
EP1837014A1 (en) *	2006-03-21	2007-09-26	Hexal Ag	Subcutaneous implants containing a degradation-resistant polylactide polymer and a LH-RH analogue
ITMI20061538A1 (it) *	2006-08-02	2008-02-03	Mediolanum Pharmaceuticals Ltd	Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
EP1917971A1 (en) *	2006-10-27	2008-05-07	Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.)	Substained release formulations comprising very low molecular weight polymers
KR100816065B1 (ko)	2006-11-27	2008-03-24	동국제약 주식회사	초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
US20080176958A1 (en)	2007-01-24	2008-07-24	Insert Therapeutics, Inc.	Cyclodextrin-based polymers for therapeutics delivery
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
RU2327459C1 (ru) *	2007-06-26	2008-06-27	Евгений Сергеевич Северин	Лекарственное средство противомикробного действия, способ получения лекарственного препарата направленного действия, содержащего наночастицы
ES2830024T3 (es)	2007-10-19	2021-06-02	Novartis Ag	Composiciones y métodos para el tratamiento del edema macular
US20090163449A1 (en) *	2007-12-20	2009-06-25	Eastman Chemical Company	Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives
US20090163603A1 (en) *	2007-12-20	2009-06-25	Eastman Chemical Company	Sulfo-polymer powder and sulfo-polymer powder blends
CA2711001A1 (en)	2007-12-26	2009-07-09	Gel-Del Technologies, Inc.	Biocompatible protein-based particles and methods thereof
TWI539959B (zh) *	2008-02-11	2016-07-01	菲瑞茵國際中心股份有限公司	治療轉移階段攝護腺癌的方法
WO2009139817A2 (en)	2008-04-15	2009-11-19	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
ES2522968T3 (es)	2008-06-04	2014-11-19	Synergy Pharmaceuticals Inc.	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en)	2008-07-16	2015-02-19	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US10016534B2 (en)	2008-11-17	2018-07-10	Gel-Del Technologies, Inc.	Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
US8822546B2 (en) *	2008-12-01	2014-09-02	Medtronic, Inc.	Flowable pharmaceutical depot
AU2010295646B2 (en)	2009-09-15	2016-02-11	Ellipses Pharma Limited	Treatment of cancer
WO2011050175A1 (en)	2009-10-21	2011-04-28	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
CN102665690A (zh) *	2009-12-22	2012-09-12	武田药品工业株式会社	缓释制剂
DE102010003615A1 (de) *	2010-04-01	2011-10-06	Leibniz-Institut Für Polymerforschung Dresden E.V.	Verfahren zur Herstellung eines Drug-Delivery-Systems auf der Basis von Polyelektrolytkomplexen
US20110300150A1 (en)	2010-05-18	2011-12-08	Scott Eliasof	Compositions and methods for treatment of autoimmune and other disease
WO2011161531A1 (en)	2010-06-24	2011-12-29	Torrent Pharmaceuticals Limited	Pharmaceutical composition containing goserelin for in-situ implant
CA2802209C (en) *	2010-06-25	2019-12-31	Takeda Pharmaceutical Company Limited	Sustained-release formulation
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012151343A1 (en)	2011-05-04	2012-11-08	Balance Therapeutics, Inc.	Pentylenetetrazole derivatives
KR101467275B1 (ko) *	2011-12-19	2014-12-02	주식회사 삼양바이오팜	분산성이 향상된 생분해성 고분자 미립자의 조성물 및 그 제조방법
KR20200108932A (ko)	2012-07-25	2020-09-21	에스에이알코드 바이오사이언스 인코포레이티드	Lfa-1 저해제 및 그의 다형체
US20140094432A1 (en)	2012-10-02	2014-04-03	Cerulean Pharma Inc.	Methods and systems for polymer precipitation and generation of particles
WO2014131024A2 (en)	2013-02-25	2014-08-28	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
HUE050050T2 (hu) *	2013-03-04	2020-11-30	Besins Healthcare Lu Sarl	Hordozórészecskékhez kötõdõ hatóanyag nanorészecskéket tartalmazó száraz gyógyászati kompozíciók
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en)	2013-03-15	2015-10-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
JP6661531B2 (ja)	2013-10-10	2020-03-11	シナジーファーマシューティカルズインコーポレイテッド	オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト
EP3079668A1 (en)	2013-12-09	2016-10-19	Durect Corporation	Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
SG11201705591PA (en)	2015-01-07	2017-08-30	Trigemina Inc	Magnesium-containing oxytocin formulations and methods of use
US9937223B2 (en)	2015-01-30	2018-04-10	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en)	2015-01-30	2017-06-27	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en)	2015-01-30	2017-08-29	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en)	2015-01-30	2017-08-29	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en)	2015-01-30	2017-09-05	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en)	2015-01-30	2018-03-27	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US10653744B2 (en)	2016-01-11	2020-05-19	Bausch Health Ireland Limited	Formulations and methods for treating ulcerative colitis
JP7093559B2 (ja)	2016-04-12	2022-06-30	トライジェミナ，インコーポレイテッド	マグネシウム含有オキシトシン製剤および使用の方法
CN105963258B (zh) *	2016-04-26	2021-01-22	广州帝奇医药技术有限公司	一种缓释微粒的制备方法
CN110954491B (zh) *	2019-12-09	2022-11-15	北京博恩特药业有限公司	用于测量醋酸戈舍瑞林缓释植入剂体外溶出度的方法
CN115666621A (zh)	2020-01-13	2023-01-31	度勒科特公司	具有减少的杂质的持续释放药物递送系统及相关方法
EP4192509A1 (en)	2020-08-05	2023-06-14	Ellipses Pharma Ltd	Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
CA3203561A1 (en)	2021-01-12	2022-07-21	Adrian Neil Verity	Sustained release drug delivery systems and related methods
WO2023012357A1 (en)	2021-08-05	2023-02-09	Medincell	Pharmaceutical composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH19942A (en) *	1980-11-18	1986-08-14	Sintex Inc	Microencapsulation of water soluble polypeptides
US4675189A (en) *	1980-11-18	1987-06-23	Syntex (U.S.A.) Inc.	Microencapsulation of water soluble active polypeptides
IE52535B1 (en) *	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US5005602A (en) *	1985-12-24	1991-04-09	Dover Corporation	Poppet valve assembly
FR2600894B1 (fr) *	1986-07-02	1989-01-13	Centre Nat Rech Scient	Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
JP2827287B2 (ja) *	1988-07-05	1998-11-25	武田薬品工業株式会社	水溶性薬物含有徐放型マイクロカプセル
US4938763B1 (en) *	1988-10-03	1995-07-04	Atrix Lab Inc	Biodegradable in-situ forming implants and method of producing the same
US4997643A (en) *	1989-07-12	1991-03-05	Union Carbide Chemicals And Plastics Company Inc.	Polymeric salt delivery systems
US5077049A (en) *	1989-07-24	1991-12-31	Vipont Pharmaceutical, Inc.	Biodegradable system for regenerating the periodontium
CH679207A5 (cs) *	1989-07-28	1992-01-15	Debiopharm Sa
WO1992000718A1 (en) *	1990-07-03	1992-01-23	Vipont Pharmaceutical, Inc.	Intragingival delivery systems for treatment of periodontal disease
CA2046830C (en) *	1990-07-19	1999-12-14	Patrick P. Deluca	Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
IL96129A0 (en) *	1990-07-20	1991-07-18	Spectronix Ltd	Method and apparatus for detecting a fire,explosion,or projectile-penetration in a monitored space
GB9211268D0 (en) *	1992-05-28	1992-07-15	Ici Plc	Salts of basic peptides with carboxyterminated polyesters
US5672659A (en) *	1993-01-06	1997-09-30	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides

1992
- 1992-05-28 GB GB@@@@A patent/GB9211268D0/en active Pending
1993
- 1993-05-11 GB GB939309645A patent/GB9309645D0/en active Pending
- 1993-05-11 IE IE930358A patent/IE74715B1/en not_active IP Right Cessation
- 1993-05-13 ZA ZA933358A patent/ZA933358B/xx unknown
- 1993-05-16 IL IL10571093A patent/IL105710A/en not_active IP Right Cessation
- 1993-05-21 TW TW082104017A patent/TW223018B/zh not_active IP Right Cessation
- 1993-05-25 CZ CZ19942937A patent/CZ292449B6/cs not_active IP Right Cessation
- 1993-05-25 SG SG1996004921A patent/SG44645A1/en unknown
- 1993-05-25 SK SK1434-94A patent/SK280320B6/sk not_active IP Right Cessation
- 1993-05-25 DE DE4392401T patent/DE4392401T1/de active Pending
- 1993-05-25 GB GB9423366A patent/GB2282066B/en not_active Expired - Fee Related
- 1993-05-25 CH CH00680/98A patent/CH690491A5/de not_active IP Right Cessation
- 1993-05-25 WO PCT/GB1993/001079 patent/WO1993024150A1/en not_active Ceased
- 1993-05-25 HU HU9403371A patent/HUT70177A/hu unknown
- 1993-05-25 JP JP6500317A patent/JPH08501064A/ja active Pending
- 1993-05-25 RU RU94046097/14A patent/RU2152225C1/ru not_active IP Right Cessation
- 1993-05-25 AT AT0901993A patent/AT407702B/de not_active IP Right Cessation
- 1993-05-25 DE DE4392401A patent/DE4392401B4/de not_active Expired - Fee Related
- 1993-05-25 ES ES09450004A patent/ES2107357B1/es not_active Expired - Fee Related
- 1993-05-25 NZ NZ252268A patent/NZ252268A/en not_active IP Right Cessation
- 1993-05-25 NL NL9320034A patent/NL195056C/nl not_active IP Right Cessation
- 1993-05-25 KR KR1019940704279A patent/KR100293882B1/ko not_active Expired - Fee Related
- 1993-05-25 AU AU40847/93A patent/AU682310B2/en not_active Ceased
- 1993-05-25 CH CH00311/94A patent/CH688911A5/de not_active IP Right Cessation
- 1993-05-25 CA CA002136751A patent/CA2136751C/en not_active Expired - Fee Related
- 1993-05-26 GR GR930100213A patent/GR1001550B/el not_active IP Right Cessation
- 1993-05-27 MC MC2243A patent/MC2330A1/fr unknown
- 1993-05-27 IT ITMI931099A patent/IT1271139B/it active IP Right Grant
- 1993-05-28 BE BE9300551A patent/BE1006143A3/fr not_active IP Right Cessation
- 1993-05-28 FR FR9306432A patent/FR2691631B1/fr not_active Expired - Fee Related
1994
- 1994-11-23 LU LU88559A patent/LU88559A1/fr unknown
- 1994-11-25 NO NO19944535A patent/NO311006B1/no unknown
- 1994-11-25 FI FI945553A patent/FI112603B/fi active
- 1994-11-28 SE SE9404115A patent/SE501970C2/sv unknown
- 1994-11-28 DK DK199401353A patent/DK176134B1/da not_active IP Right Cessation
1995
- 1995-06-07 US US08/473,303 patent/US5889110A/en not_active Expired - Fee Related
1997
- 1997-06-26 HK HK133097A patent/HK133097A/xx not_active IP Right Cessation
1999
- 1999-01-22 US US09/235,270 patent/US6034175A/en not_active Expired - Fee Related
2001
- 2001-11-16 US US09/988,068 patent/US20020198315A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CH688911A5 (de)	1998-05-29
LU88559A1 (fr)	1995-04-05
FR2691631A1 (fr)	1993-12-03
FI112603B (fi)	2003-12-31
IL105710A (en)	2001-03-19
ITMI931099A0 (it)	1993-05-27
US6034175A (en)	2000-03-07
GB9423366D0 (en)	1995-01-25
AT407702B (de)	2001-05-25
CH690491A5 (de)	2000-09-29
NL195056C (nl)	2003-07-01
WO1993024150A1 (en)	1993-12-09
IE74715B1 (en)	1997-07-30
DE4392401T1 (de)	1997-07-24
AU682310B2 (en)	1997-10-02
FI945553A0 (fi)	1994-11-25
NO311006B1 (no)	2001-10-01
JPH08501064A (ja)	1996-02-06
SK143494A3 (en)	1995-07-11
HUT70177A (en)	1995-09-28
NO944535D0 (no)	1994-11-25
NL9320034A (nl)	1995-04-03
IL105710A0 (en)	1993-09-22
GB9309645D0 (en)	1993-06-23
FR2691631B1 (fr)	1995-06-09
CZ293794A3 (en)	1995-03-15
GR1001550B (el)	1994-04-29
CA2136751C (en)	2006-10-31
BE1006143A3 (fr)	1994-05-24
GB2282066B (en)	1996-11-06
IE930358A1 (en)	1993-12-01
DE4392401B4 (de)	2007-05-16
ATA901993A (de)	2000-10-15
DK135394A (da)	1994-11-28
SE501970C2 (sv)	1995-07-03
DK176134B1 (da)	2006-09-18
ES2107357B1 (es)	1998-10-16
HU9403371D0 (en)	1995-02-28
RU94046097A (ru)	1996-09-20
FI945553L (fi)	1995-01-25
ITMI931099A1 (it)	1994-11-27
NO944535L (no)	1995-01-25
GB2282066A (en)	1995-03-29
GB9211268D0 (en)	1992-07-15
US5889110A (en)	1999-03-30
KR100293882B1 (ko)	2001-09-17
TW223018B (en)	1994-05-01
RU2152225C1 (ru)	2000-07-10
SK280320B6 (sk)	1999-11-08
CA2136751A1 (en)	1993-12-09
ZA933358B (en)	1994-09-15
SE9404115D0 (sv)	1994-11-28
AU4084793A (en)	1993-12-30
CZ292449B6 (cs)	2003-09-17
IT1271139B (it)	1997-05-27
HK133097A (en)	1997-10-24
SE9404115L (sv)	1994-11-28
US20020198315A1 (en)	2002-12-26
MC2330A1 (fr)	1994-05-31
NZ252268A (en)	1996-12-20
ES2107357A1 (es)	1997-11-16

Publication	Publication Date	Title
GB2282066B (en)	1996-11-06	Salts of peptides with carboxy-terminated polyesters
GB9223351D0 (en)	1992-12-23	Polyesters
HU9301710D0 (en)	1993-09-28	Copoliamides of terephthalic acid
GB2269176B (en)	1997-01-08	Peptides
OA09884A (en)	1994-09-15	Imidazolyl-Alkenoic Acids
EP0569146A3 (en)	1993-12-08	Polyester film
AU1081292A (en)	1992-08-13	New beta-amino- alpha-hydroxycarboxylic acids and their use
AU4246093A (en)	1993-12-13	Manufacture of terephthalic acid copolyamides
DE69323551D1 (en)	1999-03-25	Polyester
ZA938988B (en)	1994-06-08	Substituted benzoic acids
AU2850492A (en)	1993-05-27	Novel aminoalkanephosphinic acids and salts thereof
AU4332685A (en)	1985-12-12	Stabilised unsaturated polyesters
EP0215740A3 (en)	1988-09-21	Branched polyesters branched polyesters
GB9325519D0 (en)	1994-02-16	Peptides
AU4271793A (en)	1993-11-29	Novel polypeptide
ZA931299B (en)	1993-10-13	Novel peptides
HU9301617D0 (en)	1993-09-28	New thio-semicarbazone acid esters
EP0348665A3 (en)	1990-10-17	Liquid crystalline polyesters
GB9322357D0 (en)	1993-12-15	Point of sale display
ZA933757B (en)	1993-12-21	Cyclopentane-and-pentene-beta-amino acids
GB9222678D0 (en)	1992-12-09	Point of sale display
GB9210074D0 (en)	1992-06-24	Peptides
ZA935126B (en)	1995-01-16	Peptides
GB9203344D0 (en)	1992-04-01	Polyester
AU5051593A (en)	1994-05-26	Collapsible anchor